Medical Technology

@xconomy.com 3 years ago

FDA Panel Vote Weighs in Favor of Alkermes Psyche Drug, With Caveats

@xconomy.com 3 years ago

FDA Green-Lights Roche Spinal Muscular Atrophy Drug, First Oral Therapy

@xconomy.com 4 years ago

Eisai Pulls Weight Loss Drug From Market After FDA Flags Cancer Risks

@xconomy.com 4 years ago

Pfizer Taps Insilico Medicine to Use AI for Drug Target Discovery

@xconomy.com 4 years ago

Amgen’s Osteoporosis Drug Wins European Nod, With a Heart Warning

@xconomy.com 4 years ago

As Cholesterol Drug Aces Big Test, MedCo CEO Open to Flexible Pricing

@xconomy.com 4 years ago

Chasing Blueprint, Deciphera Plans FDA Filing for GI Cancer Drug

@xconomy.com 4 years ago

Can Tiny Drug Doses (and One Woman’s Fortune) Fight the Most Vicious Cancer?

@xconomy.com 5 years ago

New Data Puts Aldeyra One Step Closer to FDA Filing for Eye Drug

@xconomy.com 5 years ago

FDA OKs Depression Drug For New Moms: Fast Relief But Tough to Take

@xconomy.com 5 years ago

With New Data, Intercept On Track for First-Ever Approved NASH Drug

@xconomy.com 5 years ago

Genetic Medicine: FDA OKs 2nd Cancer Drug that Targets DNA, not Tissues

@xconomy.com 5 years ago

Alnylam Won’t Seek Quick FDA Nod For Second RNAi Drug

@xconomy.com 5 years ago

With New Data, Alnylam Could Seek Speedy OK For Second RNAi Drug

@xconomy.com 5 years ago

RNAi Hits Europe as EMA Follows FDA, Approves Alnylam Drug

@xconomy.com 5 years ago

Alnylam Gets Landmark FDA OK For First-Ever RNAi Drug

@xconomy.com 5 years ago

Sanofi Backs Click Therapeutics as Digital Medicines Gain Momentum

@xconomy.com 5 years ago

Zogenix Epilepsy Data Sets Up Market Battle With GW’s Cannabis Drug